1. Home
  2. PEW vs HURA Comparison

PEW vs HURA Comparison

Compare PEW & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PEW
  • HURA
  • Stock Information
  • Founded
  • PEW 2007
  • HURA 2009
  • Country
  • PEW United States
  • HURA United States
  • Employees
  • PEW N/A
  • HURA N/A
  • Industry
  • PEW Other Specialty Stores
  • HURA
  • Sector
  • PEW Consumer Discretionary
  • HURA
  • Exchange
  • PEW Nasdaq
  • HURA Nasdaq
  • Market Cap
  • PEW 156.5M
  • HURA 126.1M
  • IPO Year
  • PEW N/A
  • HURA N/A
  • Fundamental
  • Price
  • PEW $5.06
  • HURA $2.53
  • Analyst Decision
  • PEW Strong Buy
  • HURA Strong Buy
  • Analyst Count
  • PEW 1
  • HURA 2
  • Target Price
  • PEW $8.25
  • HURA $11.50
  • AVG Volume (30 Days)
  • PEW 1.2M
  • HURA 216.5K
  • Earning Date
  • PEW 11-14-2025
  • HURA 11-13-2025
  • Dividend Yield
  • PEW N/A
  • HURA N/A
  • EPS Growth
  • PEW N/A
  • HURA N/A
  • EPS
  • PEW N/A
  • HURA N/A
  • Revenue
  • PEW $90,690,000.00
  • HURA N/A
  • Revenue This Year
  • PEW N/A
  • HURA N/A
  • Revenue Next Year
  • PEW N/A
  • HURA N/A
  • P/E Ratio
  • PEW $45.90
  • HURA N/A
  • Revenue Growth
  • PEW N/A
  • HURA N/A
  • 52 Week Low
  • PEW $4.34
  • HURA $1.80
  • 52 Week High
  • PEW $21.40
  • HURA $8.40
  • Technical
  • Relative Strength Index (RSI)
  • PEW 42.34
  • HURA 48.47
  • Support Level
  • PEW $4.34
  • HURA $2.42
  • Resistance Level
  • PEW $5.82
  • HURA $2.64
  • Average True Range (ATR)
  • PEW 0.33
  • HURA 0.13
  • MACD
  • PEW 0.02
  • HURA 0.02
  • Stochastic Oscillator
  • PEW 49.32
  • HURA 50.00

About PEW GrabAGun Digital Holdings Inc. Common Stock

GrabAGun Digital Holdings Inc is a multi-brand eCommerce retailer of firearms, ammunition, and related accessories.

About HURA TuHURA Biosciences Inc. Common Stock

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

Share on Social Networks: